![home-bg-image.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/82522f64-905d-4f5a-a75b-c5c2d4a54f01.jpg?nearlossless=1)
![Blue-Earth logo 900400.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/6634a5f7-b7f8-4eff-9441-ac8db7123c56.jpg?nearlossless=1)
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval for its optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent, POSLUMA® (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3)
Read more- 1